Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease

Targeted Anticytokine Therapy in Patients With Chronic Heart Failure

Douglas L. Mann, John J.V. McMurray, Milton Packer et al. · Circulation · 2004 · 1.2K citations

Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases.

Paola Patrignani, Maria R. Panara, Anita Greco et al. · Journal of Pharmacology and Experimental Therapeutics · 1994 · 518 citations

Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles

Chi‐Chung Chan, S. Boyce, Christine Brideau et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 397 citations · Full text

Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease

Rémy Chenevard, David Hürlimann, Markus Béchir et al. · Circulation · 2003 · 355 citations

Cardiovascular Pharmacology, Pharmacotherapy, Coronary Artery Disease +17

Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease

Bernhard Schieffer, C Bunte, Jana Witte et al. · Journal of the American College of Cardiology · 2004 · 237 citations

Inflammation, Thrombosis, Cardiovascular Disease +12